Dr Martens issued a trading update ahead of its AGM on Thursday and it didn’t deliver any spectacular news either good or bad. That’s perhaps a relief after some the bad news that has come out of the business in recent years, but there was at least some generally positive news suggesting the company remains on track.
It said trading since the start of this financial year “has been in line with expectations and all guidance for FY26 remains unchanged”.
On a regional basis, it has “continued to see positive trading in our Americas Direct to Consumer (DTC) channel, driven by full-price sales, particularly in Retail”.
On the downside, its EMEA DTC business “remains more variable, with our UK business in particular continuing to experience a challenging trading backdrop”.
But its APAC business “continues to show good growth, with a particularly strong performance in South Korea driven by our well-established shoes category here”.
Looking ahead, its AW25 order books globally “are healthy” and even the EMEA order book is up year-on-year. The Americas order book is broadly in line year-on-year “and importantly is based on a much wider product range than previously”.
The company’s performance tends to be “H2-weighted, particularly from a profit perspective” so a healthy order book situation for the second half is a positive development.
It also said we’ll hear further details on early progress of its new consumer-first Levers for Growth strategy with its first-half results in November.
Copyright © 2025 FashionNetwork.com All rights reserved.
